TransCode Therapeutics, Inc.

NasdaqCM:RNAZ Stock Report

Market Cap: US$6.3m

TransCode Therapeutics Management

Management criteria checks 3/4

TransCode Therapeutics' CEO is Philippe Calais, appointed in Oct 2025, has a tenure of less than a year. total yearly compensation is $566.12K, comprised of 21.9% salary and 78.1% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $6.90. The average tenure of the management team and the board of directors is 7.8 years and 5.3 years respectively.

Key information

Philippe Calais

Chief executive officer

US$566.1k

Total compensation

CEO salary percentage21.87%
CEO tenureless than a year
CEO ownership0.0001%
Management average tenure7.8yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

Seeking Alpha • Aug 15

TransCode Therapeutics reports Q2 results

TransCode Therapeutics press release (NASDAQ:RNAZ): Q2 Operating loss of $4.7M. TransCode expects that its cash of $13.4 million as of June 30, 2022, is sufficient to fund planned operations into the first quarter 2023 but not for a full 12 months from the date of its financial statements.
Seeking Alpha • Jul 11

TransCode files U.S. patent application for radiotherapy based cancer treatment

TransCode Therapeutics (NASDAQ:RNAZ) on Monday said it had filed a provisional U.S. patent application directed at using radiotherapy through nanoparticles to treat cancer. The U.S. patent application is 63/356,449 and is titled "Radiolabeled Nanoparticles and Template Directed Immunomodulation for Cancer Therapy." RNAZ said the application is directed at introducing radiotherapy into the delivery of nanoparticles carrying RNA-based agonist precursors of pattern recognition receptors. RNAZ stock +3.7% to $1.39 in aftermarket trading.
Analysis Article • Apr 01

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 15

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

CEO Compensation Analysis

How has Philippe Calais's remuneration changed compared to TransCode Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$44m

Dec 31 2025US$566kUS$124k

-US$36m

Sep 30 2025n/an/a

-US$27m

Jun 30 2025n/an/a

-US$25m

Mar 31 2025n/an/a

-US$26m

Dec 31 2024US$213kn/a

-US$17m

Sep 30 2024n/an/a

-US$15m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$17m

Dec 31 2023US$113kn/a

-US$19m

Sep 30 2023n/an/a

-US$20m

Jun 30 2023n/an/a

-US$19m

Mar 31 2023n/an/a

-US$19m

Dec 31 2022US$112kn/a

-US$18m

Sep 30 2022n/an/a

-US$15m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$6m

Dec 31 2021US$53kn/a

-US$7m

Sep 30 2021n/an/a

-US$5m

Jun 30 2021n/an/a

-US$4m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020US$109kn/a

-US$2m

Compensation vs Market: Philippe's total compensation ($USD566.12K) is about average for companies of similar size in the US market ($USD647.77K).

Compensation vs Earnings: Philippe's compensation has increased whilst the company is unprofitable.

CEO

Philippe Calais (66 yo)

less than a year
Tenure
US$566,116
Compensation

Dr. Philippe P. Calais, Pharm. D. Ph.D. served as President, Chief Executive Officer and Director of MatriSys Bioscience, Inc. since January 13, 2024. Dr. Calais has been Executive Chairman of the Board of...

Leadership Team

NamePositionTenureCompensationOwnership
Philippe Calais
CEO & Executive Chairman of the Boardless than a yearUS$566.12k0.00011%
$ 6.9
Thomas Fitzgerald
CFO, President7.8yrsUS$1.07m0.00021%
$ 13.2
Zdravka Medarova
Scientific Co-Founder & Chief Scientific Officer10.3yrsno datano data
Anna Moore
Scientific Co-Founder10.3yrsno datano data
Susan Duggan
Senior Vice President of Operationsno datano datano data
Daniel Vlock
Chief Medical Officer2.2yrsno datano data
7.8yrs
Average Tenure
66yo
Average Age

Experienced Management: RNAZ's management team is seasoned and experienced (7.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Philippe Calais
CEO & Executive Chairman of the Board7.6yrsUS$566.12k0.00011%
$ 6.9
Thomas Fitzgerald
CFO, President7.8yrsUS$1.07m0.00021%
$ 13.2
Anna Moore
Scientific Co-Founder10.3yrsno datano data
Jack Stover
Independent Directorless than a yearno datano data
Elizabeth Czerepak
Independent Directorless than a yearno datano data
Phillip Zamore
Member of Scientific Advisory Board1yrno datano data
Magda Marquet
Independent Director5.3yrsUS$62.50k0%
$ 0
Keith Flaherty
Member of Advisory Boardno datano datano data
Lubomir Nechev
Member of Advisory Board5.3yrsno datano data
Frank Slack
Member of Advisory Board3.7yrsno datano data
Dejan Juric
Member of Advisory Board4.7yrsno datano data
Erik Manting
Independent Director5.4yrsUS$60.50k0%
$ 0
5.3yrs
Average Tenure
66yo
Average Age

Experienced Board: RNAZ's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/18 23:57
End of Day Share Price 2026/05/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TransCode Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarH.C. Wainwright & Co.